

Percent Change from Baseline in CFA Model
Change from baseline (%)
60
40
20
0
-20
Vehicle
1% Compound A
2% Compound A
4% Compound A
8% Compound A

FIGURE 1



Time Course of Efficiency in CCI Model
Vehicle Control
5% Lidocaine
4% Compound A (5% transcutol)
4% Compound A (10% transcutol)
Change from baseline (%)
50
40
30
20
10
0
-10
0.5
1.0
1.5
2.0
2.5
Time (h)

FIGURE 2

Percent Change from Baseline in STZ Diabetic Neuropathy Study




FIGURE 3



Percent Change from Baseline in CCI Model
Change from baseline (%)
70
60
50
40
30
20
10
0
-10
Vehicle Oral Dosage
25 mg/Kg COMPOUND A Oral Dosage
Vehicle Topical Dosage
8% (w/w) COMPOUND A Topical Dosage

FIGURE 4



Mean Plasma Concentration for COMPOUND A
Plasma concentration (ng/mL)
100
80
60
40
20
0
25 mg/Kg COMPOUND A
8% (w/w) COMPOUND A

FIGURE 5